OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy Cole, Hien Zhao, Timothy J. Collier, et al.
JCI Insight (2021) Vol. 6, Iss. 5
Open Access | Times Cited: 94
Tracy Cole, Hien Zhao, Timothy J. Collier, et al.
JCI Insight (2021) Vol. 6, Iss. 5
Open Access | Times Cited: 94
Showing 1-25 of 94 citing articles:
Evaluating drug targets through human loss-of-function genetic variation
Eric Vallabh Minikel, Konrad J. Karczewski, Hilary C. Martin, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 459-464
Open Access | Times Cited: 160
Eric Vallabh Minikel, Konrad J. Karczewski, Hilary C. Martin, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 459-464
Open Access | Times Cited: 160
Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches
Marija Vidović, Milena Rikalović
Cells (2022) Vol. 11, Iss. 11, pp. 1732-1732
Open Access | Times Cited: 93
Marija Vidović, Milena Rikalović
Cells (2022) Vol. 11, Iss. 11, pp. 1732-1732
Open Access | Times Cited: 93
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease
Hilary Grosso Jasutkar, Stephanie Oh, M. Maral Mouradian
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 207-237
Open Access | Times Cited: 70
Hilary Grosso Jasutkar, Stephanie Oh, M. Maral Mouradian
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 207-237
Open Access | Times Cited: 70
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 33
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 33
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
Scarlett J. Barker, Mai B. Thayer, Chaeyoung Kim, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 760
Closed Access | Times Cited: 22
Scarlett J. Barker, Mai B. Thayer, Chaeyoung Kim, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 760
Closed Access | Times Cited: 22
RNA dysregulation in neurodegenerative diseases
Yini Li, Shuying Sun
The EMBO Journal (2025) Vol. 44, Iss. 3, pp. 613-638
Open Access | Times Cited: 3
Yini Li, Shuying Sun
The EMBO Journal (2025) Vol. 44, Iss. 3, pp. 613-638
Open Access | Times Cited: 3
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions
Grace m. Kuo, Ramhari Kumbhar, W. Frank Blair, et al.
Molecular Neurodegeneration (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Grace m. Kuo, Ramhari Kumbhar, W. Frank Blair, et al.
Molecular Neurodegeneration (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Antisense Drugs Make Sense for Neurological Diseases
C. Frank Bennett, Holly Kordasiewicz, Don W. Cleveland
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 831-852
Open Access | Times Cited: 83
C. Frank Bennett, Holly Kordasiewicz, Don W. Cleveland
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 831-852
Open Access | Times Cited: 83
RNA-based therapeutics for neurological diseases
Karen Anthony
RNA Biology (2022) Vol. 19, Iss. 1, pp. 176-190
Open Access | Times Cited: 59
Karen Anthony
RNA Biology (2022) Vol. 19, Iss. 1, pp. 176-190
Open Access | Times Cited: 59
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
Noha Gouda, Ahmed Elkamhawy, Jungsook Cho
Biomedicines (2022) Vol. 10, Iss. 2, pp. 371-371
Open Access | Times Cited: 57
Noha Gouda, Ahmed Elkamhawy, Jungsook Cho
Biomedicines (2022) Vol. 10, Iss. 2, pp. 371-371
Open Access | Times Cited: 57
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Sindhu Menon, Sabrina E.M. Armstrong, Amir Mohammad Hamzeh, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 47
Sindhu Menon, Sabrina E.M. Armstrong, Amir Mohammad Hamzeh, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 47
A single-cell map of antisense oligonucleotide activity in the brain
Meredith A Mortberg, Juliana E Gentile, Naeem Nadaf, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 14, pp. 7109-7124
Open Access | Times Cited: 28
Meredith A Mortberg, Juliana E Gentile, Naeem Nadaf, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 14, pp. 7109-7124
Open Access | Times Cited: 28
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Franziska Richter, Miloš Stanojlović, Christopher Käufer, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 1, pp. 97-116
Open Access | Times Cited: 23
Franziska Richter, Miloš Stanojlović, Christopher Käufer, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 1, pp. 97-116
Open Access | Times Cited: 23
Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials
Min Liu, Zhiyao Wang, Huifang Shang
Journal of Neurology (2024) Vol. 271, Iss. 5, pp. 2324-2344
Open Access | Times Cited: 12
Min Liu, Zhiyao Wang, Huifang Shang
Journal of Neurology (2024) Vol. 271, Iss. 5, pp. 2324-2344
Open Access | Times Cited: 12
The Misfolding Mystery: α-syn and the Pathogenesis of Parkinson's Disease
Samir Negi, Navneet Khurana, Navneet Duggal
Neurochemistry International (2024) Vol. 177, pp. 105760-105760
Closed Access | Times Cited: 11
Samir Negi, Navneet Khurana, Navneet Duggal
Neurochemistry International (2024) Vol. 177, pp. 105760-105760
Closed Access | Times Cited: 11
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis
Jacqueline Burré, Robert H. Edwards, Glenda M. Halliday, et al.
Movement Disorders (2024) Vol. 39, Iss. 10, pp. 1663-1678
Open Access | Times Cited: 9
Jacqueline Burré, Robert H. Edwards, Glenda M. Halliday, et al.
Movement Disorders (2024) Vol. 39, Iss. 10, pp. 1663-1678
Open Access | Times Cited: 9
Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns
Shady Rahayel, Bratislav Mišić, Ying‐Qiu Zheng, et al.
Brain (2021) Vol. 145, Iss. 5, pp. 1743-1756
Open Access | Times Cited: 48
Shady Rahayel, Bratislav Mišić, Ying‐Qiu Zheng, et al.
Brain (2021) Vol. 145, Iss. 5, pp. 1743-1756
Open Access | Times Cited: 48
Role of Ubiquitin–Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance
Subhashree Sahoo, Amrita Arpita Padhy, Varsha Kumari, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 9, pp. 5379-5407
Closed Access | Times Cited: 37
Subhashree Sahoo, Amrita Arpita Padhy, Varsha Kumari, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 9, pp. 5379-5407
Closed Access | Times Cited: 37
Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases
Jacob Helm, Lüdger Schöls, Stefan Hauser
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1708-1708
Open Access | Times Cited: 34
Jacob Helm, Lüdger Schöls, Stefan Hauser
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1708-1708
Open Access | Times Cited: 34
Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
Rita Marques, Rafaela Lacerda, Luı́sa Romão
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1865-1865
Open Access | Times Cited: 33
Rita Marques, Rafaela Lacerda, Luı́sa Romão
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1865-1865
Open Access | Times Cited: 33
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
Leif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 31
Leif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 31
RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges
Jong Won Lee, Man Kyu Shim, Hyo‐Suk Kim, et al.
Advanced Drug Delivery Reviews (2023) Vol. 201, pp. 115073-115073
Open Access | Times Cited: 21
Jong Won Lee, Man Kyu Shim, Hyo‐Suk Kim, et al.
Advanced Drug Delivery Reviews (2023) Vol. 201, pp. 115073-115073
Open Access | Times Cited: 21
Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein
Poul Henning Jensen, Michael G. Schlossmacher, Leonidas Stefanis
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 378-384
Open Access | Times Cited: 20
Poul Henning Jensen, Michael G. Schlossmacher, Leonidas Stefanis
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 378-384
Open Access | Times Cited: 20
Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review
A. Rodger, Maryam N. ALNasser, Wayne G. Carter
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11022-11022
Open Access | Times Cited: 20
A. Rodger, Maryam N. ALNasser, Wayne G. Carter
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11022-11022
Open Access | Times Cited: 20
Targeting Transferrin Receptor to Transport Antisense Oligonucleotides Across the Blood-Brain Barrier
Scarlett J. Barker, Mai B. Thayer, Chaeyoung Kim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 17
Scarlett J. Barker, Mai B. Thayer, Chaeyoung Kim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 17
